SEARCH

Current Edition

AstraZeneca

As FDA scrutinizes immunotherapy approvals, Merck says Keytruda extends survival in liver cancer trial

The FDA has been under pressure to review the status of drugs granted accelerated approvals based on early data, as in some cases confirmatory trials …

Continue Reading →
Bristol Myers Squibb

GSK, in race to catch up with rivals, wins expanded approval for cancer drug

GSK has high hopes for Jemperli as it transitions to what’s being called the “new GSK,” with a greater focus on experimental drugs for infectious …

Continue Reading →
Bristol Myers Squibb

Regeneron drug extends survival in lung cancer trial, lifting company’s hopes in field

Since its first approval in first-line lung cancer in 2016, Keytruda has proved a tough competitor for rival drugmakers to challenge with their own therapies. …

Continue Reading →